Collegium Pharmaceutical Inc (NASDAQ:COLL) – Stock analysts at Jefferies Group boosted their FY2017 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a note issued to investors on Sunday. Jefferies Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will post earnings per share of ($2.58) for the year, up from their prior estimate of ($2.61). Jefferies Group has a “Buy” rating and a $32.00 price objective on the stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s Q4 2017 earnings at ($0.64) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at $0.30 EPS, FY2021 earnings at $1.62 EPS and FY2022 earnings at $2.64 EPS.

COLL has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Monday, November 13th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. BidaskClub upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, December 29th. Piper Jaffray Companies set a $19.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, November 29th. Finally, Needham & Company LLC upped their price objective on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $27.17.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at $24.37 on Wednesday. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $26.77.

In other news, Chairman Michael Thomas Heffernan sold 20,000 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $22.50, for a total transaction of $450,000.00. Following the sale, the chairman now owns 538,987 shares in the company, valued at $12,127,207.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Alison B. Fleming sold 6,928 shares of the stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total transaction of $132,116.96. Following the sale, the insider now owns 32,651 shares in the company, valued at approximately $622,654.57. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,055,558 shares of company stock worth $18,570,177. Corporate insiders own 25.76% of the company’s stock.

Large investors have recently bought and sold shares of the company. Voya Investment Management LLC purchased a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $125,000. Benjamin F. Edwards & Company Inc. boosted its holdings in Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 3,500 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 2,802 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Collegium Pharmaceutical in the fourth quarter worth approximately $176,000. Finally, JPMorgan Chase & Co. purchased a new stake in Collegium Pharmaceutical in the third quarter worth approximately $192,000. Hedge funds and other institutional investors own 82.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2018/02/14/analysts-offer-predictions-for-collegium-pharmaceutical-incs-fy2017-earnings-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.